DexCom, Inc. (NASDAQ: DXCM) has confirmed that the new Dexcom ONE Continuous Glucose Monitoring System will unveil in the United Kingdom this May. The Dexcom ONE system is a simple-to-use real-time CGM (rt-CGM) that will be more inexpensive and accessible for diabetics in the United Kingdom. Dexcom ONE is now being evaluated for inclusion in drug tariffs across the United Kingdom.
The National Institute for Health and Care Excellence (NICE) recently released updated recommendations for adults and children with Type 1 diabetes. Adults with Type 1 diabetes should now be given a choice of glucose sensors, including rt-CGM, based on their preferences, needs, characteristics, and the functioning of the devices available, according to NICE.
Dexcom ONE will be part of a range of diabetes-related devices provided by Dexcom in the UK, which includes the Dexcom G6 CGM system and the future Dexcom G7 CGM system. Dexcom ONE uses the same cutting-edge sensor technology as Dexcom G6 and is designed for those who have Type 1 or Type 2 diabetes and use insulin.
Furthermore, Dexcom ONE is a wearable sensor and transmitter that helps people manage their diabetes. The feature reduces the need for painful finger pricks by continually measuring glucose levels and delivering real-time results wirelessly to a compatible smart device via the Dexcom ONE mobile app.
Additionally, the app was developed with the user in mind. The trend arrows indicate the pace and direction that which glucose levels are moving, making treatment decisions easier in the present. Users can set up a variety of unique notifications to assist them to prevent potentially hazardous high or low glucose occurrences.